Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Answers to HCP Questions on CAR T-Cell Therapy

Listen to experts answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy for patients with hematologic malignancies.
person default
Caron A. Jacobson, MD
Jae H. Park, MD
Noopur Raje, MD
Released: July 19, 2021

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:

  • At what time in the treatment journey should CAR T-cell therapy be considered?
  • How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?
  • How is CAR T-cell therapy best used for multiple myeloma?
  • What qualities of bridging therapy are most preferred?
  • When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?
  • How are steroids optimally used in managing CAR T-cell therapy–related toxicities?


Caron A. Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Jae H. Park, MD
Associate Member  
Leukemia Service and Cellular Therapeutics Center  
Memorial Sloan Kettering Cancer Center
New York, New York

Noopur Raje, MD
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center  
Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Related Content

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.